Baidu
map

3D打印可吸收生物假体帮助患者安全重建乳房

2017-03-29 搜狐网 搜狐网

  近日,由里尔国立艺术和纺织工业学院博士Julien Payen和Pierre-Marie Danze率领的名为MAT(T)ISSE的项目已被授予法国Théophile-Legrand一等奖,该项目即使用3D打印晶格结构组织为乳腺癌幸存者重建乳腺组织的创新方法。据悉,Pierre-Marie Danze拥有里尔1大学生命与健康科学博士学位。 目前,接受女性乳房切除术的人群有两

 

近日,由里尔国立艺术和纺织工业学院博士Julien Payen和Pierre-Marie Danze率领的名为MAT(T)ISSE的项目已被授予法国Théophile-Legrand一等奖,该项目即使用3D打印晶格结构组织为乳腺癌幸存者重建乳腺组织的创新方法。据悉,Pierre-Marie Danze拥有里尔1大学生命与健康科学博士学位。

目前,接受女性乳房切除术的人群有两种主要用于乳房重建的方法:植入硅胶假体或脂肪灌注,其中包括在乳房中移植自体脂肪组织。然而,这两个程序都面临挑战,因为它们可能是危险的(在患者的健康和舒适度方面),并且非常昂贵。

由于现有两种方法的缺点,研究人员提出了一种新的生物吸收假体,可以彻底改变乳房重建手术。用于植入假体的技术来自既定方法,其中将自体脂肪组织的注射与“可再吸收的”植入物组合。由3D打印的外壳和生物可吸收的格子织物内部组成的植入物有助于支持乳房中的细胞生长。

此外,通过使用3D打印来创建植入物的外壳,医生可以使用MRI扫描确定患者的胸部形态,以此定制适应形状的植入物。一旦植入,来自患者的脂肪可以附着到植入物的类似织物的结构上,这促进了及时和自然的重建。

根据研究人员声称,乳房植入物外壳可以在大约六至八周内填充,然后重新吸收3D打印植入物,并且患者留下重建的真实感觉的乳房。Payen解释说:“这个想法是,脂肪细胞将使用花边作为支撑,来维持、增殖和改造乳房。”

如上所述,创新的MAT(T)ISSE项目最近获得了Théophile-Legrand的一等奖。 Théophile-Legrand奖项协调员Paul Schuler就获奖项目发表了评论,他说:“这是一场世界第一的一场革命”。事实上,这项突破性项目可为数千名患有乳腺癌的妇女提供乳房重建的安全有效的解决方案。

当然,任何人都可能会受益于新技术,Payen表示,3D打印可吸收的纺织生物假体仍然需要完善。他估计,在MAT(T)ISSE上市之前可能需要五到七年的时间。

据悉,创新的MAT(T)ISSE项目部分由法国里尔医院中心区域大学(CHRU)的整形外科和组织库资助。(生物谷Bioon.com)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030859, encodeId=8b5f203085941, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Nov 13 18:18:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045128, encodeId=08112045128ab, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Apr 14 20:18:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335953, encodeId=ee16133595356, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468319, encodeId=9582146831952, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030859, encodeId=8b5f203085941, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Nov 13 18:18:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045128, encodeId=08112045128ab, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Apr 14 20:18:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335953, encodeId=ee16133595356, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468319, encodeId=9582146831952, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030859, encodeId=8b5f203085941, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Nov 13 18:18:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045128, encodeId=08112045128ab, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Apr 14 20:18:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335953, encodeId=ee16133595356, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468319, encodeId=9582146831952, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2030859, encodeId=8b5f203085941, content=<a href='/topic/show?id=bdf038440bb' target=_blank style='color:#2F92EE;'>#可吸收#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38440, encryptionId=bdf038440bb, topicName=可吸收)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e03212, createdName=liao1619, createdTime=Mon Nov 13 18:18:00 CST 2017, time=2017-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045128, encodeId=08112045128ab, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Apr 14 20:18:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335953, encodeId=ee16133595356, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468319, encodeId=9582146831952, content=<a href='/topic/show?id=2d3d2e5176a' target=_blank style='color:#2F92EE;'>#假体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27517, encryptionId=2d3d2e5176a, topicName=假体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b576903125, createdName=lanyan20020088, createdTime=Fri Mar 31 06:18:00 CST 2017, time=2017-03-31, status=1, ipAttribution=)]

相关资讯

3D生物打印解决人工血管内皮化问题 你知道这是什么吗?

导读 最近,一则关于3D生物打印的血管在动物体内实验取得成功的新闻,使3D生物打印技术获得了人们的广泛关注。什么是人造血管内皮化?人造血管内皮化有什么后果?3D生物打印技术又是如何解决人工血管内皮化的问题的?最近,一则关于3D生物打印的血管在动物体内实验取得成功的新闻,使3D生物打印技术获得了人们的广泛关注。新闻中提到,这一实验的成功标志着困扰人类半个世纪的人造血管内皮化问题找到了解决办法。这则新

Baidu
map
Baidu
map
Baidu
map